Cell-based therapies are increasing in both number and application. Among the immune cell types, Natural Killer (NK) cell present themselves as an attractive option because they can target viral infections and tumor cells. They are also amenable to genetic manipulation and adoptive transfer.
NK Cell-based therapy requires the ex vivo expansion and activation of cells followed by administration to the patient. An ideal protocol for NK cell manufacturing should result consistently in the sufficient number of pure and potent cells.
In this webinar, we introduce the development of the first chemically-defined media for the expansion of NK cells derived from both peripheral blood (with and without feeder cells) and the immortalized cell line NK92.
Fill out the form below to watch the webinar recording. Make sure to opt into our mailing list to get notified of future webinars.